1. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial 
Peter R. Casson, Nanette Santoro, Karen Elkind-Hirsch, Sandra A. Carson, Peter J. Hornsby, Guy Abraham, John E. Buster 
Fertility and Sterility 
Volume 70, Issue 1, Pages (July 1998)
DOI: /S (98)

2. Figure 1
Monthly serum levels of DHEA, DHEAS, and T after daily administration of 25 mg of oral micronized DHEA (n = 6 and n = 7 in placebo and DHEA arms, respectively). These values are nadir levels at 23 hours after the dose. DHEAS, DHEA, and T all decreased toward placebo values by 6 months, indicating a time-dependent reduction in bioavailability (dose attenuation).
Fertility and Sterility  , DOI: ( /S (98) )

3. Figure 2
The ratio of insulin-like growth factor-I (IGF-I) to IGF binding protein-3 (IGFBP-3) at 3 and 6 months (n = 6 and n = 7 in placebo and DHEA arms, respectively). This ratio, thought to approximate the free IGF-I effect (12), was elevated with DHEA treatment compared with placebo. With dose attenuation, the effect was lost at 6 months.
Fertility and Sterility  , DOI: ( /S (98) )

4. Figure 3
Fasting serum high-density lipoprotein (HDL) and apolipoprotein A1 (APOA1) levels after 6 months of treatment with DHEA or placebo. Even with the previously noted dose attenuation of DHEA, HDL and apolipoprotein A1 levels were decreased by 6 months compared with placebo (n = 6 and n = 7 in placebo and DHEA arms, respectively).
Fertility and Sterility  , DOI: ( /S (98) )